BOSTON--(BUSINESS WIRE)--EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, announced today that it has commenced an underwritten public offering of shares of its common stock. EPIRUS intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering.
Help employers find you! Check out all the jobs and post your resume.
